Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.įor a complete picture of BLU-222’s drug-specific PTSR and LoA scores, buy the report here. The company utilizes its discover which combines bioinformatics and drug design capabilities to develop its medicines. Blueprint Medicines is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors and avapritinib to treat advanced systemic mastocytosis. Other CDK2 inhibitors have had ocular toxicity issues as well. Based on the underlying science on the role of CDK2 inhibition in cancer, and the potential for this mechanism to impact large populations of patients, BLU-222 represents one of the most. The FDA placed a partial hold in February amid ocular adverse event concerns, but soon lifted it. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) against non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. FDA Lifts Hold On Blueprint’s CDK2 Inhibitor Trial, Potentially Calming Nerves. It acts by targeting cyclin dependent kinase 2 (CDK2).īlueprint Medicines, formerly Hoyle Pharmaceuticals, is precision therapy company that inventing medicines for people with cancer and blood disorders. FDA Places Partial Clinical Hold on Phase I Trial of Blueprints CDK2 Inhibitor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.īLU-222 is under development for the treatment of multiple CCNE driven cancers such as ovarian, ER positive HER2 negative breast, gastric cancer, prostate cancer and endometrial cancer. Incyclix Bio Cleared by FDA to Begin Phase I/II Trial of CDK2 Inhibitor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |